Guidance on Placement of Integrated Effectiveness and Safety Summaries; Advice from FDA on Presenting Risk Information; More Warnings for Erlotinib; Sanofi-Aventis Said to Overstate Efficacy of Docetaxel; Possible Dosage Alterations for Rituximab; FDA Establishes Transparency Task Force; Unauthorized Clinical Trials Alleged; FDA Should Release Information on Unapproved Uses; Pegylated Anti-TNF Product Closer to European Approval; Viral Contaminant Reducing Supplies of Replacement Enzymes; First Follow-On Biologic Approved in Japan; More Human Embryonic Stem Cell Lines May Be Approved for Research; All Genetic Tests and Performance Data Should Be Registered; Early Development of Biologics to Gain New Regulatory Body in India; Rapid Test for C. diff. Approved; Label Changes for Immunosuppressives Reflect Concern About Kidney Virus